Taken together, TRPM8 agonists should be evaluated in various dry eye animal models to determine if they reduce dry eye symptomology and dampen TRPV1-induced inflammation and corneal opacification. This evidence concerns the gene TRPV1 and Keratoconjunctivitis sicca.